spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ATHENA trial 

 HSMN NewsFeed - 16 Feb 2016
Mentor Receives FDA IDE Approval for its ATHENA Clinical Trial
Devices FDA
 HSMN NewsFeed - 24 Apr 2014
FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 25 Feb 2013
Intravase(R) Approval Opens Vascular Market for Cytori
Regenerative Medicine FDA
 HSMN NewsFeed - 11 Oct 2012
First Patient Treated in Cytori’s U.S. Cell Therapy Heart Failure Trial
Regenerative Medicine Cardiology
 HSMN NewsFeed - 30 Jan 2012
Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE) Approved for ATHENA
Regenerative Medicine Cardiology
 HSMN NewsFeed - 30 Nov 2009
sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 28 Sep 2009
sanofi-aventis: Multaq(R) (dronedarone) Recommended for Approval in the European Union
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 28 Jul 2009
MULTAQ(R) (dronedarone) for Atrial Fibrillation or Atrial Flutter Now Available in the United States
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Jul 2009
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 18 Mar 2009
FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 11 Feb 2009
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Sep 2008
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 May 2008
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
ATHENA trial
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.